Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 0.17 0.12% 0.00
CTXR closed down 11.42 percent on Wednesday, November 20, 2024, on 2.39 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.12%
New Downtrend Bearish 0.12%
Lower Bollinger Band Walk Weakness 0.12%
New 52 Week Low Weakness 0.12%
Wide Bands Range Expansion 0.12%
Below Lower BB Weakness 0.12%
Lower Bollinger Band Touch Weakness 0.12%
Oversold Stochastic Weakness 0.12%
New 52 Week Closing Low Bearish -11.31%
Calm After Storm Range Contraction -11.31%

   Recent Intraday Alerts

Alert Time
2x Volume Pace about 2 hours ago
1.5x Volume Pace about 2 hours ago
3x Volume Pace about 2 hours ago
Down 5% about 2 hours ago
Down 3% about 2 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Citius Pharmaceuticals, Inc. Description

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Drugs Inflammation Catheter Antibiotics Cancer Care Care Products Prescription Product Prescription Products Acetamides Bloodstream Infections Lidocaine

Is CTXR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.07
52 Week Low 0.16
Average Volume 1,770,536
200-Day Moving Average 0.64
50-Day Moving Average 0.41
20-Day Moving Average 0.34
10-Day Moving Average 0.32
Average True Range 0.06
RSI (14) 29.08
ADX 25.05
+DI 14.54
-DI 35.99
Chandelier Exit (Long, 3 ATRs) 0.34
Chandelier Exit (Short, 3 ATRs) 0.34
Upper Bollinger Bands 0.51
Lower Bollinger Band 0.18
Percent B (%b) -0.03
BandWidth 95.49
MACD Line -0.05
MACD Signal Line -0.03
MACD Histogram -0.0203
Fundamentals Value
Market Cap 27.01 Million
Num Shares 159 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -0.77
Price-to-Sales 0.00
Price-to-Book 1.16
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.24
Resistance 3 (R3) 0.25 0.23 0.23
Resistance 2 (R2) 0.23 0.21 0.23 0.23
Resistance 1 (R1) 0.20 0.20 0.19 0.19 0.22
Pivot Point 0.18 0.18 0.17 0.18 0.18
Support 1 (S1) 0.15 0.16 0.14 0.15 0.12
Support 2 (S2) 0.13 0.15 0.13 0.11
Support 3 (S3) 0.10 0.13 0.11
Support 4 (S4) 0.10